Thyroid Eye Disease And Double Vision (Diplopia): Causes And Treatment Strategies
Published on: August 7, 2025
Thyroid Eye Disease And Double Vision (Diplopia): Causes And Treatment Strategies
Article author photo

Jyothsna Rao

PhD (Doctor of Philosophy) in Molecular Biology (2014)

Article reviewer photo

Jennifer Isaac

Proofreader, BA in English Literature and Spanish, The University of Southampton

Overview

Around 25-50% of the population with Graves' Disease develop a morbidity called Thyroid Eye Disease or TED. The disease causes debilitating effects like inflammation and swelling in the eye muscles due to an autoimmune reaction. Bulging eyes, redness, pain, and occasionally diplopia or double vision are among the symptoms that are seen.

Diplopia is a prevalent problem amongst the TED cohort. The patient's eyes start to produce overlapping images due to thickening and scarring of the extraocular muscles. This makes daily activities such as reading, driving, and using devices difficult. Depending on its prognosis, there are different treatment options available, ranging from non-invasive to surgical procedures.

Causes of thyroid eye disease and diplopia

Thyroid eye disease is believed to be a result of an autoimmune reaction in the ocular muscles. Many other risk factors contribute to its development:

  1. Graves’ Disease, which is a major cause of TED, affects 25-50% of individuals with the condition
  2. Genetics, wherein a family history of autoimmune thyroid disorders increases the risk
  3. Smoking is a major factor that worsens TED severity
  4. Environmental Triggers, as exposure to radioactivity, air pollutants, and stress

As the disease progresses, TED patients experience misalignment of the eyes or strabismus, leading to double vision. The severity of this can range from occasional to persistent. Several mechanisms contribute to:

  • Inflammation-induced muscle stiffness
  • Fibrosis that permanently restricts movement
  • Eyelid retraction alters eye position 
  • Orbital congestion increases pressure within the eye socket
  • In rare cases, swelling may compress the optic nerve, further aggravating vision problems and impaired depth perception, making tasks like walking or driving difficult

Symptoms of thyroid eye disease and diplopia

Thyroid Eye Disease (TED) symptoms progress through 3 different stages:

  • The Mild stage, where signs like dry eyes, redness, irritation, and excessive tearing are observed
  • Moderate stage, when symptoms like proptosis, eyelid swelling, light sensitivity, and pain with eye movement are reported
  • Severe stage, where the patient experiences diplopia, difficulty in closing the eyelids, ulcerations in the cornea, and loss of vision due to optic nerve compression

It is very important to differentiate TED-related Diplopia from other conditions like Myasthenia gravis. In Myasthenia gravis, double vision worsens with muscle fatigue and is often accompanied by drooping eyelids or ptosis, while TED involves eyelid retraction and eye bulging or proptosis.

  • Patients with TED-related diplopia experience a hierarchy in the loss of function of the extraocular muscles as per the IMSLO rule. While the oblique muscles are the least affected, the inferior rectus is most impacted. Along with double vision, symptoms like headaches, difficulty focusing, and impaired depth perception make tasks like walking or driving difficult

Diagnosis of thyroid eye disease and diplopia

It is vital to diagnose Thyroid Eye Disease (TED) with precision, especially the severity of Diplopia. This will help in working out an effective treatment plan and also prevent complications. The diagnostic process generally follows this order:

  • Initial Clinical Evaluation, to assess symptoms and risk factors
  • Eye Movement Tests for examining eye alignment and muscle involvement
  • CT or MRI scans to detect orbital inflammation, muscle thickening, and any optic nerve compression
  • Conducting routine thyroid function tests (T3, T4, TSH) to confirm thyroid dysfunction
  • Assessment of the eyes' focus and clarity by
  • Measuring the degree of eye misalignment 

Treatment and management of thyroid eye disease and diplopia  

A cut-throat comprehensive treatment plan with medicines, surgery, and holistic healing is required for TED.

Non-surgical approach for the active phase

When the disease is still in the active stage, to reduce inflammation and stop further muscle damage, corticosteroids are frequently used. In more severe situations, drugs like methotrexate, rituximab, or teprotumumab, which suppress the immune system, may work well.

To overcome the vision overlapping during this stage of the illness, prism lenses are suggested. They merge double images, helping patients perform daily activities with ease. Botox injections can also be considered to relax overactive muscles, improving eye alignment for a limited period of time. Lastly, any smokers are encouraged to quit at this stage of treatment, as cigarettes trigger symptoms.

Surgical approach for the stable phase

By the time the chronic phase of TED sets in, inflammation decreases, and permanent muscular fibrosis develops. The strabismus surgery is the only way to reverse the disease's consequences. The surgery helps to restore alignment and improve vision clarity.

For cases of severe eye bulging, additional space in the eye socket is created by excising a portion of the eye through the process of orbital decompression. This helps to reduce the patient’s discomfort and mental agony.

Eyelid retraction can also be rectified surgically. These surgical alternatives can significantly improve the quality of life and raise the confidence of individuals affected by chronic TED.

Complications of thyroid eye disease (TED) and untreated diplopia

Serious consequences like corneal and optical nerve damage, glaucoma, and vision loss can result from untreated diplopia and thyroid eye disease (TED). If ignored, diplopia can lead to migraines, trouble judging distances, and emotional trauma. Therefore, recognising and resolving these issues is crucial.

Risk factors for TED and diplopia

Many factors can raise the risk of developing severe Thyroid Eye Disease (TED) and diplopia. Poorly managed Graves' disease and smoking increase inflammation and the severity of the disease. Additionally, environmental factors like prior treatment with radioactive iodine may also trigger TED.  

Once diagnosed, early intervention must be done to avoid long-term complications like muscle fibrosis and permanent eye misalignment.

Summary

Thyroid Eye Disease (TED) is an exhaustive condition seen in most of the Graves’ disease patients. Eye muscles and tissues are weakened, creating symptoms which can lead to diplopia or double vision. A plethora of factors like genetics, immunological and environmental responses influence the condition. The disease progresses through three different stages, starting as a mild redness, bulging eyes and then turning into full-blown 

diplopia. To diagnose TED, assessments of eye movements, thyroid profile testing and evaluation of symptoms must be completed.

The management of TED and diplopia needs a multidisciplinary approach, involving many specialists, ranging from endocrinologists, ophthalmologists, and surgeons. The severity defines the type of treatment, such as corticosteroids and prism lenses, to orbital decompression surgery in chronic cases. Lifestyle changes and early intervention can improve prognosis and enhance life quality for patients.

References

  1. Johnson BT, Jameyfield E, Aakalu VK. Optic neuropathy and diplopia from thyroid eye disease: update on pathophysiology and treatment. Current Opinion in Neurology. 2020 Dec 4;34(1):116–21. 
  2. Moledina M, Damato EM, Lee V. The changing landscape of thyroid eye disease: current clinical advances and future outlook. Eye. 2024 Feb 19;
  3. Wiersinga WM, Bartalena L. Epidemiology and Prevention of Graves’ Ophthalmopathy. Thyroid. 2002 Oct;12(10):855–60.
  4. Bahn RS. Graves’ Ophthalmopathy. New England Journal of Medicine [Internet]. 2010 Feb 25;362(8):726–38. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902010/ 
  5. Patel A, Yang H, Douglas RS. A New Era in the Treatment of Thyroid Eye Disease. American Journal of Ophthalmology. 2019 Dec;208:281–8. 
  6. Ramesh S, Zhang Q (Ed), Sharpe J, Penne R, Haller J, Lum F, et al. Thyroid Eye Disease (TED) and its Vision Threatening Manifestations in the Academy IRIS® Registry: 2014-2018. American Journal of Ophthalmology [Internet]. 2023 May 17 [cited 2023 Jun 11]; Available from https://www.sciencedirect.com/science/article/pii/S000293942300185X
  7. Tellez M, Cooper J, Edmonds C. Graves’ ophthalmopathy in relation to cigarette smoking and ethnic origin. Clinical Endocrinology. 1992 Mar;36(3):291–4.
  8. Stan MN, Bahn RS. Risk Factors for Development or Deterioration of Graves’ Ophthalmopathy. Thyroid. 2010 Jul;20(7):777–83.
Share

Jyothsna Rao

PhD (Doctor of Philosophy) in Molecular Biology (2014)

arrow-right